Cyprotex Acquires Apredica

Contract Research Organisation Cyprotex which specialises in the preclinical ADME assessment of drug candidates has moved to acquire the issued share capital of Apredica LCL, a US-based CRO specialising in preclinical ADME and Toxicology assessment. Immediately preceding this move, Apredica had acquired the Intellectual Property and all other assets necessary for offering the Cellular Systems Biology (CSB™) and High Content Toxicology services previously offered by Cellumen, Inc.

The total consideration for the acquisition of Apredica is £2.68 million to be satisfied through a combination of 44,730,297 new Cyprotex shares and £1 million in cash. The transaction was unanimously recommended by the Boards of both Cyprotex and Apredica, and does not require shareholder approval.

The combined organisation has operations in the world’s two largest centres of drug discovery, Europe and North America with little overlap in their customer bases, the company reports. Cyprotex’s entry into the in vitro toxicology market, will soon be further bolstered by the Company’s new toxicology laboratory in Macclesfield, due to open this October.